```json
{
"content": [
{
"type": "paragraph",
"content": "North America leads the Glutamic Acid Decarboxylase ELISA Test Kit market growth, accounting for 35% of global revenue. Key drivers include high adoption of advanced diagnostics for autoimmune neurological disorders, robust R&D investments, and a mature healthcare infrastructure. Regulatory support for precision medicine further accelerates market expansion in the region."
},
{
"type": "paragraph",
"content": "Europe follows with 30% market share, driven by stringent healthcare policies promoting early diagnosis, strong public-private partnerships, and a well-established ecosystem for neurology research. The region’s aging population also fuels demand for diagnostic tools targeting neurodegenerative diseases."
},
{
"type": "paragraph",
"content": The Asia Pacific region is the fastest-growing market, projected to expand at a 12% CAGR through 2030. Rising awareness of autoimmune conditions, government initiatives to improve diagnostic access in rural areas, and increasing healthcare investments are pivotal. China and India dominate due to their large patient pools and growing biotechnology sectors."
},
{
"type": "paragraph",
"content": Latin America (8% share) and the Middle East & Africa (2% share) exhibit slower growth but show potential. Latin America benefits from improving healthcare infrastructure and cross-border collaborations, while MEA’s market is driven by partnerships with global diagnostic firms and gradual policy reforms to address diagnostic gaps."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 35 },
{ "name": "Europe", "value": 30 },
{ "name": "Asia Pacific", "value": 25 },
{ "name": "Latin America", "value": 8 },
{ "name": "Middle East & Africa", "value": 2 }
]
}
}
```
